Polyrizon (Nasdaq: PLRZ) signs 3 key U.S. sites for NASARIX allergy trial

Rhea-AI Filing Summary

Polyrizon Ltd. reports clinical progress for its NASARIX™ (PL-14) program, signing agreements with two additional U.S. clinical sites and bringing the total to three major contracted centers for its upcoming trial. These sites are described as the largest and most strategically important in its planned multi-center study and are expected to provide the highest patient enrollment.

The trial will evaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis, with up to five U.S. sites expected to participate. NASARIX™ is an intranasal hydrogel intended to form a protective barrier in the nasal cavity to block airborne allergens. The study will follow international Good Clinical Practice standards and support the company’s broader regulatory strategy.

Key Figures

Contracted U.S. clinical sites: 3 sites Planned total clinical sites: Up to 5 sites Clinical indication: Seasonal allergic rhinitis

3 metrics

Contracted U.S. clinical sites 3 sites Largest and most strategically important centers for NASARIX trial

Planned total clinical sites Up to 5 sites Multi-center NASARIX trial in the United States

Clinical indication Seasonal allergic rhinitis Condition targeted by NASARIX Allergy Blocker study

Key Terms

development-stage biotech company, intranasal hydrogel, seasonal allergic rhinitis, Good Clinical Practice (GCP), +2 more

6 terms

development-stage biotech company financial

"Polyrizon Ltd. (Nasdaq: PLRZ) ... a development-stage biotech company specializing in the development of innovative intranasal hydrogels"

intranasal hydrogel medical

"The NASARIX™ investigational product is an intranasal hydrogel formulation intended to create a protective physical barrier"

seasonal allergic rhinitis medical

"The study will evaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis"

Seasonal allergic rhinitis, commonly called hay fever, is an immune reaction that causes sneezing, runny or blocked nose, itchy eyes and throat when a person inhales seasonal airborne allergens like pollen. For investors it matters because it drives predictable demand for allergy medicines, over‑the‑counter products and clinical trials, affects workforce productivity and healthcare spending, and can influence sales seasonality the same way an annual weather pattern shapes retail demand.

Good Clinical Practice (GCP) regulatory

"The trial will be conducted in accordance with international Good Clinical Practice (GCP) standards and applicable regulatory requirements"

Capture and Contain TM (C&C) hydrogel technology technical

"Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks"

Trap and Target, or T&T technical

"Polyrizon refers to its additional technology ... focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of June 2026

Commission file number: 001-42375

Polyrizon Ltd.

(Translation of registrant’s name into English)

8 Ha-Pnina Street

Raanana, 4321545, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on June 8, 2026, titled “Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial.”

The first, second, third, fifth, sixth and seventh paragraphs of the press release attached to this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-284410 and 333-288923) and Form F-3 (333-291368), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Polyrizon Ltd.
Date: June 8, 2026	By:	/s/ Tomer Izraeli
	Name:	Tomer Izraeli
	Title:	Chief Executive Officer

3

Exhibit 99.1

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial

Raanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced it has signed agreements with two additional U.S. clinical sites. This brings the total to three major contracted sites for its upcoming NASARIX™ (PL-14) clinical study.

These three sites represent the largest and most strategically important centers in the Company’s planned multi-center clinical trial and are expected to contribute the highest rates of patient enrollment. The study will evaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis.

This progress follows the Company’s recent announcement of its first U.S. clinical site, which the Company believes shows strong execution of its clinical plan.

“We are very encouraged by the rapid expansion of our clinical site network, particularly with the addition of two highly experienced and high-enrollment centers,” said Tomer Izraeli, CEO of Polyrizon. “We believe that securing the three leading sites early positions us strongly for efficient patient recruitment and timely study execution as we prepare to initiate our multi-center clinical trial.”

The study, titled “Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients with Seasonal Allergic Rhinitis,” is designed as a multi-center trial in the United States, with up to five clinical sites expected to participate.

The NASARIX™ investigational product is an intranasal hydrogel formulation intended to create a protective physical barrier in the nasal cavity to block airborne allergens at the point of entry, potentially offering a non-pharmacological approach to allergy prevention.

The trial will be conducted in accordance with international Good Clinical Practice (GCP) standards and applicable regulatory requirements, supporting the Company’s broader regulatory strategy.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain ^TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials and studies , how the new clinical sites are expected to contribute the highest rates of patient enrolment and its belief that securing the three leading sites early positions it strongly for efficient patient recruitment and timely study execution as we prepare to initiate our multi-center clinical trial.  Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

FAQ

What did Polyrizon (PLRZ) announce in its NASARIX clinical update?

Polyrizon announced agreements with two additional U.S. clinical sites, bringing the total to three major centers for its upcoming NASARIX™ (PL-14) trial in seasonal allergic rhinitis, highlighting progress in building its planned multi-center study network.

How many clinical sites are planned for Polyrizon’s NASARIX (PL-14) trial?

The NASARIX trial is designed as a multi-center study in the United States with up to five clinical sites expected to participate. Three major U.S. sites are already contracted and are described as the largest and most strategically important centers in the study.

What condition will Polyrizon’s NASARIX Allergy Blocker study target?

The NASARIX Allergy Blocker study will target patients with seasonal allergic rhinitis. The trial will assess safety, tolerability, and efficacy of the intranasal hydrogel product, which is intended to create a physical barrier in the nasal cavity to block airborne allergens.

How does Polyrizon describe the NASARIX investigational product?

Polyrizon describes NASARIX as an intranasal hydrogel formulation designed to create a protective physical barrier in the nasal cavity. It aims to block airborne allergens at the point of entry, potentially offering a non-pharmacological approach to allergy prevention for seasonal allergic rhinitis.

Under what standards will Polyrizon’s NASARIX trial be conducted?

The NASARIX trial will be conducted in accordance with international Good Clinical Practice (GCP) standards and applicable regulatory requirements. Polyrizon states that this study framework supports its broader regulatory strategy for developing its intranasal hydrogel technologies and allergy-focused products.

What technologies is Polyrizon (PLRZ) developing besides NASARIX?

Polyrizon is developing medical device hydrogels delivered as nasal sprays using its Capture and Contain (C&C) technology, intended as a “biological mask” barrier. It is also advancing Trap and Target (T&T) technology, at an earlier pre-clinical stage, focused on nasal delivery of active pharmaceutical ingredients.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE TITLED: "POLYRIZON MAKES STRONG CLINICAL PROGRESS: SECURES THREE U 10.8 KB